Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure ; day:4 ; month:11 ; year:2020 ; pages:1-20
Heart failure reviews ; (4.11.2020), 1-20
- Urheber
-
Dutka, Mieczysław
Bobiński, Rafał
Ulman-Włodarz, Izabela
Hajduga, Maciej
Bujok, Jan
Pająk, Celina
Ćwiertnia, Michał
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10741-020-10041-1
- URN
-
urn:nbn:de:101:1-2020121721054202002885
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dutka, Mieczysław
- Bobiński, Rafał
- Ulman-Włodarz, Izabela
- Hajduga, Maciej
- Bujok, Jan
- Pająk, Celina
- Ćwiertnia, Michał
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care